Important Administration Instructions

Always check insulin labels before administration [see Warnings and Precautions (5.4)].

•

Inspect NOVOLIN R visually before use. It should appear clear and colorless. Do not use NOVOLIN R if particulate matter or coloration is seen.

•

Use of NOVOLIN R in insulin pumps is not recommended because of the risk of precipitation.

Route of Administration

Subcutaneous Administration

•

Inject NOVOLIN R subcutaneously approximately 30 minutes prior to the start of a meal into the abdominal area, buttocks, thigh, or the upper arm.

•

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and ​localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2), Adverse Reactions (6)].

•

​During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].

Intravenous Administration

•

Administer NOVOLIN R intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels to reduce the risk of hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.6) and How Supplied/Storage and Handling (16.2)].

•

Dilute NOVOLIN R to concentrations from 0.05 unit/mL to 1 unit/mL insulin in infusion systems using polypropylene infusion bags. NOVOLIN R is stable in infusion fluids such as 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/L potassium chloride.

Dosage Information

•

Individualize and adjust the dosage of NOVOLIN R based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.

•

NOVOLIN R given by subcutaneous injection should generally be used in regimens that include an intermediate or long-acting insulin.

•

Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see Warnings and Precautions (5.2, 5.3) and Use in Specific Populations (8.6,8.7)].

•

Dosage adjustment may be needed when switching from another insulin to NOVOLIN R [see Warnings and Precautions (5.2)].

Dosage Adjustment due to Drug Interactions

•

Dosage adjustment may be needed when NOVOLIN R is co-administered with certain drugs [see Drug Interactions (7)].

Instructions for Mixing with Other Insulins for Subcutaneous Injection

•

NOVOLIN R can be mixed with isophane insulin human suspension.

•

When mixing, the NOVOLIN R should be drawn into the syringe first and the mixture should be injected immediately after mixing.